Steven Seedhouse
Stock Analyst at Cantor Fitzgerald
(3.20)
# 1,154
Out of 5,055 analysts
161
Total ratings
47.24%
Success rate
1.05%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ATXS Astria Therapeutics | Downgrades: Neutral | n/a | $12.57 | - | 3 | Nov 12, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Overweight | $24 → $26 | $7.08 | +267.23% | 2 | Oct 15, 2025 | |
| DNTH Dianthus Therapeutics | Reiterates: Outperform | $56 → $63 | $40.85 | +54.22% | 4 | Sep 9, 2025 | |
| KRRO Korro Bio | Maintains: Strong Buy | $153 → $147 | $6.07 | +2,321.75% | 3 | Aug 13, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $77 → $82 | $71.45 | +14.77% | 20 | Aug 7, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $7.08 | +41.24% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $23.57 | +18.80% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $1.35 | +640.74% | 14 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $39.11 | +165.92% | 20 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $2.16 | +918.52% | 2 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $6 → $14 | $2.17 | +545.16% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $125.02 | -25.61% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $28.35 | +139.86% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $20.33 | +421.40% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $5.86 | +155.97% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $18.79 | +198.03% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $8.70 | +555.17% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $4.08 | +439.22% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $2.60 | +553.85% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $3.05 | +1,047.54% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $64.94 | -41.48% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $70.80 | +0.28% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $2.71 | +84.50% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $33.82 | +12.36% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $7.27 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.04 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $13.03 | +1,972.94% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $167.55 | - | 2 | Apr 23, 2020 |
Astria Therapeutics
Nov 12, 2025
Downgrades: Neutral
Price Target: n/a
Current: $12.57
Upside: -
BioCryst Pharmaceuticals
Oct 15, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $7.08
Upside: +267.23%
Dianthus Therapeutics
Sep 9, 2025
Reiterates: Outperform
Price Target: $56 → $63
Current: $40.85
Upside: +54.22%
Korro Bio
Aug 13, 2025
Maintains: Strong Buy
Price Target: $153 → $147
Current: $6.07
Upside: +2,321.75%
Mirum Pharmaceuticals
Aug 7, 2025
Maintains: Strong Buy
Price Target: $77 → $82
Current: $71.45
Upside: +14.77%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $7.08
Upside: +41.24%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $23.57
Upside: +18.80%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $1.35
Upside: +640.74%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $39.11
Upside: +165.92%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $2.16
Upside: +918.52%
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $2.17
Upside: +545.16%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $125.02
Upside: -25.61%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $28.35
Upside: +139.86%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $20.33
Upside: +421.40%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $5.86
Upside: +155.97%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $18.79
Upside: +198.03%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $8.70
Upside: +555.17%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $4.08
Upside: +439.22%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $2.60
Upside: +553.85%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $3.05
Upside: +1,047.54%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $64.94
Upside: -41.48%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $70.80
Upside: +0.28%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $2.71
Upside: +84.50%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $33.82
Upside: +12.36%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $7.27
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.04
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $13.03
Upside: +1,972.94%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $167.55
Upside: -